CAMBRIDGE, Mass., April 1 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced that the U.S. Food and Drug
Administration (FDA) will convene a Dermatologic and Opthalmic Drugs Advisory
Committee on May 23, 2002 to review the registrational filing of Biogen's drug
AMEVIVE(R) (alefacept) for the treatment of moderate-to-severe chronic plaque
psoriasis.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Biogen filed its application for AMEVIVE on August 6, 2001 in both the
U.S. and in Europe.
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from worldwide sales of AVONEX for
treatment of relapsing forms of multiple sclerosis, and from the sales by
licensees of a number of products. (Please see full prescribing information at
http://www.avonex.com.) Biogen's research and development activities are
focused on novel products to treat inflammatory and autoimmune diseases,
neurological diseases, cancer, fibrosis and congestive heart failure. The
Company maintains active clinical research programs in protein therapeutics,
small molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
Media Contact:
Amy McKnight
Associate Director, Public Affairs
Biogen, Inc.
Tel: (617) 679-2723
Investment Community Contact:
Elizabeth Woo
Director, Investor Relations
Biogen, Inc.
Tel: (617) 679-2822
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/101550.html
CONTACT:
Media Contact: Amy McKnight, Associate
Director, Public Affairs, +1-617-679-2723, or Investment
Community Contact: Elizabeth Woo, Director, Investor Relations,
+1-617-679-2822, both of Biogen, Inc.
|
